Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA347947
Max Phase: Preclinical
Molecular Formula: C25H30N6O5
Molecular Weight: 494.55
Molecule Type: Small molecule
Associated Items:
ID: ALA347947
Max Phase: Preclinical
Molecular Formula: C25H30N6O5
Molecular Weight: 494.55
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCOC(=O)CCC(NC(=O)c1ccc(NCc2ccc3nc(N)nc(N)c3c2)cc1)C(=O)OCC
Standard InChI: InChI=1S/C25H30N6O5/c1-3-35-21(32)12-11-20(24(34)36-4-2)29-23(33)16-6-8-17(9-7-16)28-14-15-5-10-19-18(13-15)22(26)31-25(27)30-19/h5-10,13,20,28H,3-4,11-12,14H2,1-2H3,(H,29,33)(H4,26,27,30,31)
Standard InChI Key: LPCYHYYLOMBMSO-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 494.55 | Molecular Weight (Monoisotopic): 494.2278 | AlogP: 2.41 | #Rotatable Bonds: 11 |
Polar Surface Area: 171.55 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 11 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 7.05 | CX LogP: 2.01 | CX LogD: 1.87 |
Aromatic Rings: 3 | Heavy Atoms: 36 | QED Weighted: 0.29 | Np Likeness Score: -0.77 |
1. Crippen GM.. (1980) Quantitative structure-activity relationships by distance geometry: systematic analysis of dihydrofolate reductase inhibitors., 23 (6): [PMID:7392027] [10.1021/jm00180a004] |
2. Ghose AK, Crippen GM.. (1982) Quantitative structure-activity relationship by distance geometry: quinazolines as dihydrofolate reductase inhibitors., 25 (8): [PMID:7120278] [10.1021/jm00350a003] |
3. Chen BK, Horváth C, Bertino JR.. (1979) Multivariate analysis and quantitative structure-activity relationships. Inhibition of dihydrofolate reductase and thymidylate synthetase by quinazolines., 22 (5): [PMID:110930] [10.1021/jm00191a005] |
4. Hansch C, Fukunaga JY, Jow PY.. (1977) Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines., 20 (1): [PMID:319234] [10.1021/jm00211a020] |
Source(1):